R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Sales Director Rare Disease - Rare Disease Commercial, EU4+UK Region

Full-Time
€110.3k - €183.8k/yr
Expert
Bachelor's
Munich, Germany
HybridHybrid office-based role; travel of 50% or more across the EU4+UK region is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A Bachelor's degree is required.
  • A minimum of 10 years of experience in the pharmaceutical or biotechnology industry is required.
  • A minimum of 3 years of experience in a first-line field sales management role is required.
  • Proven success hiring, mentoring, developing, and retaining high-performing teams is required.
  • The ability to operate within sophisticated multi-stakeholder account environments is required.
  • Knowledge of market access and reimbursement frameworks across EU4+UK markets is required.
  • The ability to mentor teams on value-based and access-oriented payer engagement is required.
  • Experience with Veeva CRM, Salesforce effectiveness tools, data analytics, and digital promotion is required.
  • Knowledge of EFPIA and applicable national pharmaceutical industry codes is required.
  • The ability to travel 50% or more across EU4+UK and hold a valid driving licence is required.
  • Strong leadership, communication, and interpersonal skills in multicultural environments are required.
Responsibilities
  • Lead a sales team across EU4+UK to deliver company objectives.
  • Drive account targeting, segmentation, and multichannel customer engagement.
  • Set performance objectives and lead coaching, development, and succession planning.
  • Align incentive compensation plans with brand strategies and targets.
  • Partner with Commercial Operations on training, analytics, key performance indicators, Veeva CRM, and territory alignment.
  • Provide field insights on customer feedback, patient journey barriers, and competitive intelligence.
  • Partner with cross-functional team members to address market trends and dynamics.
  • Champion excellence, accountability, and patient-centricity across the organization.
Desired Qualifications
  • An advanced degree in life sciences, pharmacy, medicine, or business is strongly preferred.
  • Experience in rare disease, specialized medicines, or gene therapy/advanced therapy medicinal product commercialization is preferred.
  • Proficiency in English and one additional European language, such as French, German, Italian, or Spanish, is highly desirable.
  • Established key opinion leader relationships in rare metabolic, musculoskeletal, or hearing loss areas are desirable.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 12th, 2026
Regeneron's Pasatru shows zero new bone lesions in adult FOP patients at 84 weeks

Regeneron Pharmaceuticals said its drug Pasatru (garetosmab-grts) showed sustained results in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes bone to grow in muscle and connective tissue. The 84-week data from the Phase 3 OPTIMA trial were presented at the American Society for Bone and Mineral Research annual meeting. From week 56 to week 84, patients on Pasatru had no new abnormal bone lesions, against nine for placebo. New flare-ups numbered one on the 10 mg/kg dose, 14 on the 3 mg/kg dose, and 17 on placebo. The trial enrolled 63 adults. Skin and soft tissue infections rose with dose but all resolved, and no patients stopped treatment because of them. The US Food and Drug Administration recently approved Pasatru. A trial in children and adolescents is planned to begin later this year.

Republican National Committee
Oct 9th, 2026
TODAY: President Trump rallies in Syracuse.

TODAY: President Trump rallies in Syracuse. Commentary. If you are covering President Trump's rally in Syracuse today, please consider this statement from the Republican National Committee: "Kathy Hochul is the worst governor in America and wants to keep New York a high-tax, pro-crime, sanctuary state. New Yorkers are sick of it and fired up to welcome President Trump and Republicans like Bruce Blakeman who will fight for all New Yorkers by standing with law enforcement, lowering costs, and bringing back common sense." - RNC Spokesperson Kristen Cianci Background: President Trump And Republicans Delivered Historic Tax Cuts * The Working Families Tax Cuts saved each New Yorker an average $4,079 in taxes. * New York will see wages increase by up to $8,000 over the next four years. * The expanded SALT cap delivered $32.2 billion in tax savings. * 5% of New York workers benefit from no tax on tips. * Up to 62% of New York workers benefit from no tax on overtime. * 3.3 million seniors in New York benefit from no tax on Social Security. President Trump Is Delivering Major Investments Across New York * President Trump has secured $11.2 trillion in direct foreign investments that are fueling job growth, innovation, and opportunity. * Micron raised its planned U.S. investments to more than $250 billion through 2035 for its new semiconductor manufacturing plant in Clay, New York, fourteen miles from Syracuse. * Anheuser-Busch invested $9 million into its Baldwinsville, New York, brewery near Syracuse to increase production of its alcohol brands. * GlobalFoundries announced $16 billion in investment to increase domestic semiconductor production and advanced packaging capabilities, including at its Malta, New York facility. * IBM announced plans to invest $150 billion into the United States over the next five years, including into its manufacturing plant in Poughkeepsie, New York. * Regeneron invested $2 billion into a new drug manufacturing facility in Saratoga County, creating 1,000 new jobs. * Chobani announced a $1.2 billion investment in a new manufacturing facility in Rome, New York. Thanks To President Trump Violent Crime Has Fallen At Historic Rates * In 2026, in New York, murders fell by 48%, and New York City saw the fewest shootings and murders in recorded history. * Operation Tidal Wave 1.0 arrested two people in Albany, New York, during a fraud investigation that led to the seizure of over 130 illegal firearms. * Operation Tidal Wave 2.0 arrested over 40 people in Albany, New York, in connection with drug distribution and illegal firearms. * Francisco Javier Roman-Bardales, a high-ranking member of MS-13, was charged in the Eastern District of New York for narco-terrorism, racketeering, material support for terrorism, and alien-smuggling conspiracies. * Operation Rotten Apple arrested nearly 2,200 illegal aliens across New York, including murderers, rapists, pedophiles, drug traffickers, and violent criminals. * Operation Salvo arrested 54 people in an immigration enforcement surge in New York following the shooting of a CBP officer; among those arrested are members of transnational gangs responsible for drug and weapon trafficking and human smuggling.

PR Newswire
Oct 8th, 2026
Gene therapy restores hearing in 9 of 12 children with inherited deafness

A gene therapy treatment has restored hearing in children born deaf due to inherited OTOF gene variants. In a clinical trial, nine of 12 children with profound deafness gained meaningful hearing after receiving Otarmeni (lunsotogene parvec-cwha), developed by Regeneron. The treatment delivers a working copy of the otoferlin gene directly into the cochlea using a dual AAV1 vector. By 24 weeks, four patients achieved normal to near-normal hearing, whilst four others had mild to moderate hearing loss. Cincinnati Children's Hospital treated two siblings as part of the trial. Three-year-old Abdu went from hearing virtually nothing to normal range hearing within weeks. His one-year-old sister Sumaya also showed dramatic improvement. The therapy addresses OTOF-related congenital deafness, which accounts for approximately 1% of congenital deafness cases. Results were published in The New England Journal of Medicine.

MarketScreener
Oct 6th, 2026
Regeneron Pharmaceuticals, Inc. announces presentation of new clinical research at European Society for Medical Oncology Congress 2026.

Regeneron Pharmaceuticals, Inc. announces presentation of new clinical research at European Society for Medical Oncology Congress 2026. Published on 10/06/2026 at 02:20 pm EDT S&P Capital IQ Regeneron Pharmaceuticals, Inc. announced the presentation of new clinical research at the European Society for Medical Oncology (ESMO) Congress 2026, taking place from October 23-27 in Madrid, Spain. Highlights from the company?s 10 abstracts will cover new data and analyses from trials in cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma and cancer-associated thrombosis. The potential uses of neoadjuvant Libtayo in CSCC, ubamatamab, cenvacibart and amrecibart described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority. Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune(R) technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced NSCLC and advanced cervical cancer. In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab. The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors. (C) S&P Capital IQ - 2026

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.